연구동향 분석

Optimal Timing of Zoster Vaccination After Shingles: A Prospective Study of the Immunogenicity and Safety of Live Zoster Vaccine

이은영 전준영 송경호 최평균 방지환 김의석 김홍빈 박상원 김남중 박완범 오명돈 2018년

논문상세정보
인용/피인용

' Optimal Timing of Zoster Vaccination After Shingles: A Prospective Study of the Immunogenicity and Safety of Live Zoster Vaccine' 의 참고문헌

  • Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine
    Weinberg A [2009]
  • Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine
    Levin MJ [2008]
  • Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy
    Kim JW [2015]
  • Vaccination against shingles: 2015/16, Information for healthcare professionals
  • Update on the Use of Herpes Zoster Vaccine
  • Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials
  • The lifetime occurrence of herpes zoster and prevalence of post-herpetic neuralgia: a retrospective survey in an elderly population
    Bowsher D [1999]
  • The incidence of herpes zoster
    Donahue JG [1995]
  • The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine
    Schmader K [2008]
  • The clinical course of herpes zoster: a prospective study in primary care
    Helgason S [1996]
  • The Australian immunisation handbook
  • Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster
    Mills R [2010]
  • Recommendations of the Advisory Committee on Immunization Practices for use of herpes zoster vaccines
    Dooling KL [2018]
  • Population based study of herpes zoster and its sequelae
  • Immunization to reduce the frequency and severity of herpes zoster and its complications
    Oxman MN [1995]
  • Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population
    Tseng HF [2012]
  • Herpes zoster recurrences more frequent than previously reported
    Yawn BP [2011]
  • Fold rise in antibody titers by measured by glycoprotein-based enzyme-linked immunosorbent assay is an excellent correlate of protection for a herpes zoster vaccine, demonstrated via the vaccine efficacy curve
    Gilbert PB [2014]
  • Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales
    van Hoek AJ [2009]
  • Clinical practice: herpes zoster
    Cohen JI [2013]
  • Cellular and humoral responses to a second dose of herpes zoster vaccine administered 10 years after the first dose among older adults
    Levin MJ [2016]